Evripidis Gavathiotis

Bakx Therapeutics is a company based in DE that focuses on developing more effective and precise therapeutics that utilize the mitochondrial apoptosis pathway. The American company's proprietary codynx™ drug discovery platform integrates computational and experimental capabilities to collaborate with researchers in validated biological pathways. Bakx's leading asset, partnered with Ipsen, is focused on activating the bax protein to treat cancer and age-related diseases. Bakx Therapeutics, Inc. was co-founded by world-leading researchers in apoptosis and computationally aided drug discovery. Sree Kant has been the CEO of the company since 2020.

Stelexis Therapeutics LLC focuses on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations. The company was founded by Ulrich Steidl, Derrick Rossi, Amit Verma, Evripidis Gavathiotis, and Roman Perez-Soler in 2017 and is headquartered in New York ,NY.